BiotechTube

AUBE00 + Cetuximab

Phase 1Recruiting
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Solid Tumors

Conditions

Solid Tumors

Trial Timeline

Jun 5, 2025 → Dec 31, 2029

NCT ID
NCT07030959

About AUBE00 + Cetuximab

AUBE00 + Cetuximab is a phase 1 stage product being developed by Chugai Pharmaceutical for Solid Tumors. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07030959. Target conditions include Solid Tumors.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT07030959Phase 1Recruiting

Competing Products

20 competing products in Solid Tumors

See all competitors
ProductCompanyStageHype Score
E7050EisaiPhase 1
33
AFM24 + Atezolizumab 840 MG in 14 ML InjectionAffimedPhase 1/2
33
EXS21546BiotrialPhase 1/2
33
SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent)Syros PharmaceuticalsPhase 1
25
BBP-398 + sotorasibBridgeBio PharmaPhase 1
30
BBP-398 (Formerly known as IACS-15509)BridgeBio PharmaPhase 1
30
SON-1010Sonnet BioTherapeuticsPhase 1
28
SON-1010Sonnet BioTherapeuticsPhase 1/2
36
RC220 + Doxorubicin (Adriamycin)Race OncologyPhase 1
25
BT1718Bicycle TherapeuticsPhase 1/2
33
NL-201 + Pembrolizumab Injection [Keytruda]NeurogenePhase 1
25
ZN-c3 + Carboplatin + Pegylated liposomal doxorubicin + Paclitaxel + Gemcitabine + BevacizumabZentalis PharmaceuticalsPhase 1
25
AzenosertibZentalis PharmaceuticalsPhase 1
25
IMC-18F1Eli LillyPhase 1
33
OKI-179OnKure TherapeuticsPhase 1
25
LY3499446 + Abemaciclib + Cetuximab + Erlotinib + DocetaxelEli LillyPhase 1/2
41
ACR-2316Acrivon TherapeuticsPhase 1
25
agenT-797 + Approved ICIsMiNK TherapeuticsPhase 1
25
LY3300054 + Ramucirumab + Abemaciclib + Merestinib + LY3321367Eli LillyPhase 1
33
BBP-398LianBioPhase 1
25

Other Products from Chugai Pharmaceutical

Satralizumab 120 mgApproved
85
Pegasys® + Pegasys®Approved
85
ED-71 + Alfacalcidol + ED-71 placebo + Alfacalcidol placeboPhase 3
77
R744 + Epoetin betaPhase 3
77
EmicizumabPhase 3
77